| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Shanghai Junshi Biosciences Co. Ltd (HK: 1877)
1877 Technical Analysis
4
| As on 12th Dec 2025 1877 STOCK Price closed @ 24.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 20.43 & Strong Buy for SHORT-TERM with Stoploss of 11.96 we also expect STOCK to react on Following IMPORTANT LEVELS. |
1877STOCK Price
| Open | 23.60 | Change | Price | % |
| High | 24.36 | 1 Day | 0.50 | 2.13 |
| Low | 23.22 | 1 Week | 0.30 | 1.27 |
| Close | 24.00 | 1 Month | -2.58 | -9.71 |
| Volume | 3709800 | 1 Year | 11.38 | 90.17 |
| 52 Week High 36.84 | 52 Week Low 10.30 | ||||
HK Hong Kong Most Active Stocks
| 1341 | 0.09 | 12.50% |
| 1060 | 0.86 | 3.61% |
| 0020 | 2.21 | 4.74% |
| 1359 | 1.38 | -2.82% |
| 43 | 1.14 | 0.00% |
| 0020-OL | 2.11 | -1.40% |
| 0939 | 7.64 | 0.79% |
| CSHK100 | 2317.75 | 1.82% |
| 1810 | 42.96 | 1.85% |
| 1288 | 5.55 | -2.97% |
HK Hong Kong Top Gainers Stocks
HK Hong Kong Top Losers Stocks
| 1877 Daily Charts |
1877 Intraday Charts |
Whats New @ Bazaartrend |
1877 Free Analysis |
|
|
1877 Important Levels Intraday
| RESISTANCE | 26.20 |
| RESISTANCE | 25.49 |
| RESISTANCE | 25.06 |
| RESISTANCE | 24.62 |
| SUPPORT | 23.38 |
| SUPPORT | 22.94 |
| SUPPORT | 22.51 |
| SUPPORT | 21.80 |
1877 Forecast December 2025
| 4th UP Forecast | 29.67 |
| 3rd UP Forecast | 27.85 |
| 2nd UP Forecast | 26.73 |
| 1st UP Forecast | 25.6 |
| 1st DOWN Forecast | 22.4 |
| 2nd DOWN Forecast | 21.27 |
| 3rd DOWN Forecast | 20.15 |
| 4th DOWN Forecast | 18.33 |
1877 Weekly Forecast
| 4th UP Forecast | 27.12 |
| 3rd UP Forecast | 26.12 |
| 2nd UP Forecast | 25.50 |
| 1st UP Forecast | 24.88 |
| 1st DOWN Forecast | 23.12 |
| 2nd DOWN Forecast | 22.50 |
| 3rd DOWN Forecast | 21.88 |
| 4th DOWN Forecast | 20.88 |
1877 Forecast2025
| 4th UP Forecast | 78.84 |
| 3rd UP Forecast | 61.25 |
| 2nd UP Forecast | 50.38 |
| 1st UP Forecast | 39.51 |
| 1st DOWN Forecast | 8.49 |
| 2nd DOWN Forecast | -2.38 |
| 3rd DOWN Forecast | -13.25 |
| 4th DOWN Forecast | -30.84 |
Shanghai Junshi Biosciences Co. Ltd ( HK Hong Kong Symbol : 1877 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
1877 Business Profile
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients, as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China. Address: Building 2, Shanghai, China, 201203
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service